^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Aqupla (nedaplatin) (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study
Published date:
01/06/2022
Excerpt:
All patients with NAC received 1-5 cycles of platinum-containing (carboplatin, cisplatin, or nedaplatin) chemotherapy....The progression-free survival (PFS) of BRCAmut patients was significantly reduced after NAC (median: 14.9 vs. 18.5 months; p=0.023); however, there was no difference in overall survival (OS) (median: 75.1 vs. 72.8 months; p=0.798).
DOI:
10.3389/fonc.2021.810099
